secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2025-05-06T23:59:59+00:00
Accession:  0001724521-25-000061
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Arcus Q1 net loss widens to $112M; cash $1.0B; casdatifan Phase 3 to start Q2
-----------------------------------------------------------------------------

- Revenue fell to $28M from $145M YoY; full-year 2025 revenue guidance $75M-$90M.
- Net loss of $112M vs $4M in Q1 2024; R&D expenses rose to $122M from $109M.
- Cash, equivalents, marketable securities $1.0B; sufficient to fund through initial pivotal readouts.
- Phase 3 PEAK-1 trial of casdatifan + cabozantinib in ccRCC expected to initiate Q2 2025.
- FDA feedback on etrumadenant supports registrational path but Arcus not pursuing Phase 3 now.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000172452125000061/0001724521-25-000061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000172452125000061/rcus-20250506.htm
  HTML page:      https://secwatch.observer/filing/0001724521-25-000061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer